The Need for Axillary Dissection in Patients with Positive Axillary Sentinel Lymph Nodes
The need for completion axillary dissection after a positive sentinel node biopsy continues to be challenged. In the 2 years since we last reviewed this subject, a number of authors have shared their experiences about micrometastatic disease and isolated tumor cells, opining both for and against axi...
Gespeichert in:
| Veröffentlicht in: | Current oncology reports 2011-02, Vol.13 (1), p.5-10 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10 |
|---|---|
| container_issue | 1 |
| container_start_page | 5 |
| container_title | Current oncology reports |
| container_volume | 13 |
| creator | Croshaw, Randal L. Erb, Kathleen M. Shapiro-Wright, Hilary M. Julian, Thomas B. |
| description | The need for completion axillary dissection after a positive sentinel node biopsy continues to be challenged. In the 2 years since we last reviewed this subject, a number of authors have shared their experiences about micrometastatic disease and isolated tumor cells, opining both for and against axillary treatment. Data from the ACOSOG Z0011 trial and other small studies do not appear to support the use of completion axillary dissection even for macro-metastatic disease in patients with clinically node-negative (N0) disease. While existing guidelines still recommend axillary dissection for patients with clinically positive nodes, even when conversion to clinically negative disease following neoadjuvant chemotherapy has occurred, this concept is being questioned in ACOSOG Z1071 and in several other recent small trials. The surgical approach to the treatment of breast cancer continues to move away from the traditional Halstedian concept. |
| doi_str_mv | 10.1007/s11912-010-0133-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_822555124</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>822555124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-6d1699fe329aa47664dc78e5dbc05ff0f5a44619cfc477737858dc4eb87964793</originalsourceid><addsrcrecordid>eNp9kE1PAjEQhhujEUR_gBfTm6fV6dd2eyT4mRAkERNvzdKdlRLYxe2i8u8tAfXmYdJJ5pk304eQcwZXDEBfB8YM4wkwiCVEAgeky5SQScpTc7jtuUiENtAhJyHMAThABsekw8EoLZXpktfJDOkIsaBl3dD-l18s8mZDb3wI6FpfV9RXdJy3Hqs20E_fzui4Dr71H_hHP8ehr3BBh5vlakZHdYHhlByV-SLg2f7tkZe728ngIRk-3T8O-sPECSnaJC1YakyJgps8lzpNZeF0hqqYOlBlCaXKpUyZcaWTWmuhM5UVTuI00yaV2ogeudzlrpr6fY2htUsfHMbDKqzXwWacK6UYl5FkO9I1dQgNlnbV-GW83zKwW59259NGn3br00Lcudinr6dLLH43fgRGgO-AEEfVGzZ2Xq-bKv74n9RvGn1_zQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>822555124</pqid></control><display><type>article</type><title>The Need for Axillary Dissection in Patients with Positive Axillary Sentinel Lymph Nodes</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Croshaw, Randal L. ; Erb, Kathleen M. ; Shapiro-Wright, Hilary M. ; Julian, Thomas B.</creator><creatorcontrib>Croshaw, Randal L. ; Erb, Kathleen M. ; Shapiro-Wright, Hilary M. ; Julian, Thomas B.</creatorcontrib><description>The need for completion axillary dissection after a positive sentinel node biopsy continues to be challenged. In the 2 years since we last reviewed this subject, a number of authors have shared their experiences about micrometastatic disease and isolated tumor cells, opining both for and against axillary treatment. Data from the ACOSOG Z0011 trial and other small studies do not appear to support the use of completion axillary dissection even for macro-metastatic disease in patients with clinically node-negative (N0) disease. While existing guidelines still recommend axillary dissection for patients with clinically positive nodes, even when conversion to clinically negative disease following neoadjuvant chemotherapy has occurred, this concept is being questioned in ACOSOG Z1071 and in several other recent small trials. The surgical approach to the treatment of breast cancer continues to move away from the traditional Halstedian concept.</description><identifier>ISSN: 1523-3790</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-010-0133-0</identifier><identifier>PMID: 20957459</identifier><language>eng</language><publisher>New York: Current Science Inc</publisher><subject>Axilla ; Humans ; Lymph Node Excision - methods ; Lymph Nodes - pathology ; Lymph Nodes - surgery ; Lymphatic Metastasis ; Medicine ; Medicine & Public Health ; Neoplasms - pathology ; Neoplasms - surgery ; Oncology ; Practice Guidelines as Topic ; Risk Assessment ; Sentinel Lymph Node Biopsy - methods</subject><ispartof>Current oncology reports, 2011-02, Vol.13 (1), p.5-10</ispartof><rights>Springer Science+Business Media, LLC 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-6d1699fe329aa47664dc78e5dbc05ff0f5a44619cfc477737858dc4eb87964793</citedby><cites>FETCH-LOGICAL-c343t-6d1699fe329aa47664dc78e5dbc05ff0f5a44619cfc477737858dc4eb87964793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11912-010-0133-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11912-010-0133-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20957459$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Croshaw, Randal L.</creatorcontrib><creatorcontrib>Erb, Kathleen M.</creatorcontrib><creatorcontrib>Shapiro-Wright, Hilary M.</creatorcontrib><creatorcontrib>Julian, Thomas B.</creatorcontrib><title>The Need for Axillary Dissection in Patients with Positive Axillary Sentinel Lymph Nodes</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><addtitle>Curr Oncol Rep</addtitle><description>The need for completion axillary dissection after a positive sentinel node biopsy continues to be challenged. In the 2 years since we last reviewed this subject, a number of authors have shared their experiences about micrometastatic disease and isolated tumor cells, opining both for and against axillary treatment. Data from the ACOSOG Z0011 trial and other small studies do not appear to support the use of completion axillary dissection even for macro-metastatic disease in patients with clinically node-negative (N0) disease. While existing guidelines still recommend axillary dissection for patients with clinically positive nodes, even when conversion to clinically negative disease following neoadjuvant chemotherapy has occurred, this concept is being questioned in ACOSOG Z1071 and in several other recent small trials. The surgical approach to the treatment of breast cancer continues to move away from the traditional Halstedian concept.</description><subject>Axilla</subject><subject>Humans</subject><subject>Lymph Node Excision - methods</subject><subject>Lymph Nodes - pathology</subject><subject>Lymph Nodes - surgery</subject><subject>Lymphatic Metastasis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasms - pathology</subject><subject>Neoplasms - surgery</subject><subject>Oncology</subject><subject>Practice Guidelines as Topic</subject><subject>Risk Assessment</subject><subject>Sentinel Lymph Node Biopsy - methods</subject><issn>1523-3790</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1PAjEQhhujEUR_gBfTm6fV6dd2eyT4mRAkERNvzdKdlRLYxe2i8u8tAfXmYdJJ5pk304eQcwZXDEBfB8YM4wkwiCVEAgeky5SQScpTc7jtuUiENtAhJyHMAThABsekw8EoLZXpktfJDOkIsaBl3dD-l18s8mZDb3wI6FpfV9RXdJy3Hqs20E_fzui4Dr71H_hHP8ehr3BBh5vlakZHdYHhlByV-SLg2f7tkZe728ngIRk-3T8O-sPECSnaJC1YakyJgps8lzpNZeF0hqqYOlBlCaXKpUyZcaWTWmuhM5UVTuI00yaV2ogeudzlrpr6fY2htUsfHMbDKqzXwWacK6UYl5FkO9I1dQgNlnbV-GW83zKwW59259NGn3br00Lcudinr6dLLH43fgRGgO-AEEfVGzZ2Xq-bKv74n9RvGn1_zQ</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Croshaw, Randal L.</creator><creator>Erb, Kathleen M.</creator><creator>Shapiro-Wright, Hilary M.</creator><creator>Julian, Thomas B.</creator><general>Current Science Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110201</creationdate><title>The Need for Axillary Dissection in Patients with Positive Axillary Sentinel Lymph Nodes</title><author>Croshaw, Randal L. ; Erb, Kathleen M. ; Shapiro-Wright, Hilary M. ; Julian, Thomas B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-6d1699fe329aa47664dc78e5dbc05ff0f5a44619cfc477737858dc4eb87964793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Axilla</topic><topic>Humans</topic><topic>Lymph Node Excision - methods</topic><topic>Lymph Nodes - pathology</topic><topic>Lymph Nodes - surgery</topic><topic>Lymphatic Metastasis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasms - pathology</topic><topic>Neoplasms - surgery</topic><topic>Oncology</topic><topic>Practice Guidelines as Topic</topic><topic>Risk Assessment</topic><topic>Sentinel Lymph Node Biopsy - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Croshaw, Randal L.</creatorcontrib><creatorcontrib>Erb, Kathleen M.</creatorcontrib><creatorcontrib>Shapiro-Wright, Hilary M.</creatorcontrib><creatorcontrib>Julian, Thomas B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Croshaw, Randal L.</au><au>Erb, Kathleen M.</au><au>Shapiro-Wright, Hilary M.</au><au>Julian, Thomas B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Need for Axillary Dissection in Patients with Positive Axillary Sentinel Lymph Nodes</atitle><jtitle>Current oncology reports</jtitle><stitle>Curr Oncol Rep</stitle><addtitle>Curr Oncol Rep</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>13</volume><issue>1</issue><spage>5</spage><epage>10</epage><pages>5-10</pages><issn>1523-3790</issn><eissn>1534-6269</eissn><abstract>The need for completion axillary dissection after a positive sentinel node biopsy continues to be challenged. In the 2 years since we last reviewed this subject, a number of authors have shared their experiences about micrometastatic disease and isolated tumor cells, opining both for and against axillary treatment. Data from the ACOSOG Z0011 trial and other small studies do not appear to support the use of completion axillary dissection even for macro-metastatic disease in patients with clinically node-negative (N0) disease. While existing guidelines still recommend axillary dissection for patients with clinically positive nodes, even when conversion to clinically negative disease following neoadjuvant chemotherapy has occurred, this concept is being questioned in ACOSOG Z1071 and in several other recent small trials. The surgical approach to the treatment of breast cancer continues to move away from the traditional Halstedian concept.</abstract><cop>New York</cop><pub>Current Science Inc</pub><pmid>20957459</pmid><doi>10.1007/s11912-010-0133-0</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3790 |
| ispartof | Current oncology reports, 2011-02, Vol.13 (1), p.5-10 |
| issn | 1523-3790 1534-6269 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_822555124 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Axilla Humans Lymph Node Excision - methods Lymph Nodes - pathology Lymph Nodes - surgery Lymphatic Metastasis Medicine Medicine & Public Health Neoplasms - pathology Neoplasms - surgery Oncology Practice Guidelines as Topic Risk Assessment Sentinel Lymph Node Biopsy - methods |
| title | The Need for Axillary Dissection in Patients with Positive Axillary Sentinel Lymph Nodes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A03%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Need%20for%20Axillary%20Dissection%20in%20Patients%20with%20Positive%20Axillary%20Sentinel%20Lymph%20Nodes&rft.jtitle=Current%20oncology%20reports&rft.au=Croshaw,%20Randal%20L.&rft.date=2011-02-01&rft.volume=13&rft.issue=1&rft.spage=5&rft.epage=10&rft.pages=5-10&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-010-0133-0&rft_dat=%3Cproquest_cross%3E822555124%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=822555124&rft_id=info:pmid/20957459&rfr_iscdi=true |